The mission of AbVacc is to utilize structure-based design for development of next generation vaccines and immunotherapeutics for treatment of infectious and inflammatory diseases. Building upon 15 years of research under the parent company Integrated BioTherapeutics, AbVacc now has a vibrant pipeline of monoclonal antibodies and engineered vaccines in advanced preclinical with several candidate entering the clinical stage in the next few years. To accomplish its ambitious goals, AbVacc has focused on a public-private funding strategy and partnered with various Government funding agencies, primarily National Institute of Allergy and Infectious Diseases (NIAID) and CARB-X as well as private funding sources such as Novo Holdings Repair Impact Fund. Further strategic partnerships include EliteImmune Corp., Scripps Research Institute, La Jolla Institute for Immunology, ViroVax, LLC, University of Texas Medical Branch, Johns Hopkins University, University of Rochester, University of Maryland, and Washington University.

AbVacc operations will remain at 4 research Court, Suite 310, Rockville, MD.